Welcome to our dedicated page for Medicenna Therapeutics news (Ticker: MDNAF), a resource for investors and traders seeking the latest updates and insights on Medicenna Therapeutics stock.
Medicenna Therapeutics reports developments as a clinical-stage immunotherapy company developing proprietary Superkines for cancer, autoimmune and inflammatory diseases. Recurring updates center on MDNA11, a long-acting IL-2 Superkine; MDNA113, a tumor-targeted and conditionally activated anti-PD-1 x IL-2 bifunctional Superkine; and bizaxofusp, formerly MDNA55, an IL-4 Empowered Superkine studied in glioblastoma.
Company news also includes clinical and preclinical data presentations at oncology and healthcare conferences, corporate and financial updates, collaborations around investigator-initiated trials, and governance changes such as board and medical leadership appointments.
Medicenna reported significant survival benefits for recurrent glioblastoma (rGBM) patients treated with bizaxofusp at the 2024 ASCO Annual Meeting.
The Phase 2b study showed that a single treatment increased median overall survival (mOS) by 88% (13.5 vs. 7.2 months, p=0.009) and reduced the risk of death by nearly half (hazard ratio: 0.54, 95% confidence interval: 0.34-0.83) compared to a matched external control arm.
Additionally, bizaxofusp improved one-year and two-year overall survival rates by 180% and 290%, respectively. Importantly, these benefits were observed irrespective of IL-4 receptor expression, broadening the potential patient pool for future studies.
The findings indicate that tumor control could serve as an early surrogate for survival benefits.
Medicenna announced promising results from the Phase 1/2 ABILITY-1 study of MDNA11, showing durable single-agent activity in patients with advanced solid tumors. A pancreatic cancer patient achieved 100% lesion regression over 104 weeks, maintaining remission 4 months post-treatment. A melanoma patient also showed 100% regression of target lesions. No dose-limiting toxicities were observed, even when combined with Keytruda, allowing dose escalation to 90µg/kg. The study reported significant immune activation, particularly in CD8+ T and NK cells, suggesting MDNA11's potential as a next-generation IL-2 super-agonist.
Medicenna Therapeutics Corp., a clinical-stage immunotherapy company, will present updates on the MDNA11 ABILITY-1 Trial at the Sachs 10th Annual Oncology Innovation Forum on May 31, 2024. The event precedes the ASCO Annual Meeting in Chicago, where Medicenna will showcase Phase 1/2 trial data on MDNA11, a long-acting IL-2 super-agonist, in patients with advanced tumors. The study examines MDNA11 as a monotherapy and in combination with pembrolizumab. Medicenna's President and CEO, Dr. Fahar Merchant, will lead the presentation and engage in one-on-one meetings during the event. Additionally, Medicenna will present data on bizaxofusp for recurrent glioblastoma at ASCO 2024.
Medicenna provided an update on its presentations at the 2024 ASCO Annual Meeting, highlighting ASCO's withdrawal of the MDNA11 abstract due to alleged prior publication policy violations. Despite disagreements, Medicenna plans to share high-impact data from the ABILITY-1 trial virtually. The company aims to demonstrate the potential of MDNA11 as an IL-2 super-agonist with promising clinical results.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.